SARS-CoV-2疫苗接种及单克隆抗体对CD19靶向CAR-T细胞治疗后结局的影响:EPICOVIDEHA调查
这项多中心回顾性研究基于EPICOVIDEHA调查数据,纳入64例既往接受CD19靶向CAR-T细胞治疗后感染COVID-19的患者。COVID-19相关总死亡率为31%,奥密克戎变异株感染者的死亡风险显著低于既往变异株(7% vs 58%,P=.012),仅单克隆抗体治疗似乎有效降低死亡率(从32%降至0%,P=.036)。
要点
- CD19靶向CAR-T治疗后COVID-19相关总死亡率为31%。
- 奥密克戎变异株感染死亡风险显著低于既往变异株(7% vs 58%,P=.012)。
- 仅单克隆抗体治疗似乎有效降低死亡率(从32%降至0%,P=.036)。
核心结论
- CAR-T细胞接受者感染COVID-19后的生存率随时间改善,既往疫苗接种联合单克隆抗体治疗显著降低其死亡风险。
研究设计与样本
- 多中心回顾性研究,数据来自EPICOVIDEHA调查,共识别64例既往接受CD19靶向CAR-T细胞治疗后感染COVID-19的患者。
- 试验注册号为NCT04733729。
主要发现
- COVID-19所致总死亡率为31%。
- 奥密克戎变异株感染者死于COVID-19的风险显著低于既往变异株感染者(7% vs 58%,P=.012)。
- 诊断时已接种疫苗者26例,接种两剂疫苗显示COVID-19所致死亡风险有下降但未达统计学显著(33.3% vs 14.2%,P=.379)。
- 病程似乎更轻,ICU入住更少(39% vs 14%,P=.054),住院时间更短(7天 vs 27.5天,P=.022)。
- 在可选治疗方案中,仅单克隆抗体似乎有效降低死亡率(从32%降至0%,P=.036)。
关键数值与推荐
- 奥密克戎变异株感染者死于COVID-19的风险为7%,既往变异株感染者为58%(P=.012)。
- 接种两剂疫苗者COVID-19所致死亡风险为14.2%,未接种/未完成两剂者为33.3%(P=.379,未达统计学显著)。
- 单克隆抗体治疗者死亡率为0%,未接受单克隆抗体治疗者为32%(P=.036)。
临床怎么用
- 作者结论认为CAR-T细胞接受者感染COVID-19后的生存率随时间改善,既往疫苗接种联合单克隆抗体治疗显著降低死亡风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with previous CD19-directed chimeric antigen receptor (CAR) T-cell therapy have a prolonged vulnerability to viral infections. Coronavirus disease 2019 (COVID-19) has a great impact and has previously been shown to cause high mortality in this population. Until now, real-world data on the impact of vaccination and treatment on patients with COVID-19 after CD19-directed CAR T-cell therapy are lacking. Therefore, this multicenter, retrospective study was conducted with data from the EPICOVIDEHA survey. Sixty-four patients were identified. The overall mortality caused by COVID-19 was 31%. Patients infected with the Omicron variant had a significantly lower risk of death due to COVID-19 compared with patients infected with previous variants (7% vs 58% [P = .012]). Twenty-six patients were vaccinated at the time of the COVID-19 diagnosis. Two vaccinations showed a marked but unsignificant reduction in the risk of COVID-19-caused mortality (33.3% vs 14.2% [P = .379]). In addition, the course of the disease appears milder with less frequent intensive care unit admissions (39% vs 14% [P = .054]) and a shorter duration of hospitalization (7 vs 27.5 days [P = .022]). Of the available treatment options, only monoclonal antibodies seemed to be effective at reducing mortality from 32% to 0% (P = .036). We conclude that survival rates of CAR T-cell recipients with COVID-19 improved over time and that the combination of prior vaccination and monoclonal antibody treatment significantly reduces their risk of death. This trial was registered at www.clinicaltrials.gov as #NCT04733729.
引用
- van Doesum JA, Salmanton-García J, Marchesi F, et al. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey. Blood Adv. 2023. PMID: 37058479. doi:10.1182/bloodadvances.2022009578
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。